{'fraction_non_alphanumeric': 0.020050125313283207, 'fraction_numerical': 0.017543859649122806, 'mean_word_length': 5.549180327868853, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
The effect of apraclonidine on the intraocular pressure of glaucoma patients following Nd:YAG laser posterior capsulotomy.

We retrospectively compared the incidence and level of postoperative intraocular pressure (IOP) spikes in 53 consecutive glaucoma patients undergoing Nd:YAG posterior capsulotomy (YPC) who received apraclonidine immediately postoperatively, with those occurring in 22 consecutive similar patients who did not receive apraclonidine. Postoperative IOP elevations of 5 mm Hg or more occurred in 13% of the apraclonidine recipients and in 59% of the nonrecipients; elevations of 10 mm Hg or more occurred in 4% of the former and in 27% of the latter. Our results suggest that apraclonidine can be a useful adjunct in preventing IOP elevations following YPC in glaucoma patients.